Trust Investment Advisors Sells 26,439 Shares of Pfizer Inc. (NYSE:PFE)

Trust Investment Advisors trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 59.1% in the 4th quarter, HoldingsChannel reports. The firm owned 18,278 shares of the biopharmaceutical company’s stock after selling 26,439 shares during the quarter. Trust Investment Advisors’ holdings in Pfizer were worth $485,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the 4th quarter worth $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer during the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer during the fourth quarter valued at about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by company insiders.

Pfizer Price Performance

Pfizer stock opened at $25.56 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $144.96 billion, a price-to-earnings ratio of 18.13, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm has a 50-day moving average of $26.14 and a two-hundred day moving average of $27.00. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PFE. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.